Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Alessandro Passardi 1, * , Emanuela Scarpi 2, * , Luigi Cavanna 3 , Monia Dall’Agata 2 , Davide Tassinari 4 , Silvana Leo 5 , Ilaria Bernardini 6 , Fabio Gelsomino 7 , Stefano Tamberi 8 , Alba A. Brandes 9 , Elena Tenti 10 , Roberto Vespignani 11 , Giovanni L. Frassineti 1 , Dino Amadori 1 , Ugo De Giorgi 1 1 Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 2 Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola, Italy 3 Medical Oncology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy 4 Department of Oncology, Infermi Hospital, Rimini, Italy 5 Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy 6 Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy 7 Oncology Unit, University Hospital Modena, Modena, Italy 8 Oncology Unit, Degli Infermi Hospital, Faenza, Italy 9 Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy 10 Oncology Pharmacy Laboratory, IRST IRCCS, Meldola, Italy 11 IT Service, IRST IRCCS, Meldola, Italy * These authors have contributed equally to this work Correspondence to: Emanuela Scarpi, e-mail: emanuela.scarpi@irst.emr.it Keywords: metastatic colorectal cancer, bevacizumab, SII NLR PLR, prognosis Received: February 24, 2016 Accepted: April 04, 2016 Published: April 21, 2016 ABSTRACT Background: To investigate the role of pre-treatment inflammatory indexes (II) as predictors of prognosis and treatment efficacy in patients with metastatic colorectal cancer mCRC randomized onto the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT) with or without bevacizumab (Bev). Results: In the overall population, PFS and OS were higher in patients with low SII ( p = .015 and .002, respectively), low NLR ( p = .0001 and <.0001, respectively) and low PLR ( p = .004 and .008, respectively). Patients with low NLR in the CT plus Bev arm had a higher PFS than those treated with CT alone (HR = 0.69, p = .021). Patients and Methods: Two hundred and eighty-nine patients were considered for this study, 141 receiving CT plus Bev and 148 receiving CT alone. The pre-treatment systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were evaluated to identify a potential correlation with progression-free (PFS) and overall survival (OS) in both the overall population and the 2 treatment arms. Conclusion: Our results indicate that II, in particular NLR, are good prognostic and predictive markers for mCRC patients who are candidates for CT plus Bev.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 2×
“It has increasingly been recognized that tumor infiltrating inflammatory cells are responsible for producing inflammatory mediators and cytokines that induce angiogenesis, tumor growth, invasion and metastasis [3-5].”
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“In addition to promoting tumor angiogenesis, there is evidence that VEGF favors tumor immune evasion and immune response suppression through different mechanisms mainly regulated by myeloid-derived suppressor cells (MDSCs) [30].”
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Bevacizumab (Bev) is a humanized monoclonal antibody with antiangiogenic activity that binds to the vascular endothelial growth factor (VEGF), leading to the inhibition of the circulating ligand and to the prevention of receptor activation [1].”
Hu, B., Yang, X.-R., Xu, Y., Sun, Y.-F., Sun, C., Guo, W., Zhang, X., Wang, W.-M., Qiu, S.-J., Zhou, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0442 · Cited by 2,493 · cited 2×
“The systemic immuneinflammation index (SII) was recently investigated as a prognostic marker in several malignancies including renal cell carcinoma, small cell lung cancer and hepatocellular carcinoma [19-22].”
Labelle, M., Begum, S., & Hynes, R. O. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.009 · Cited by 1,833
Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis
Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., & Ferri, L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67484 · Cited by 1,395
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593 · cited 3×
“com/oncotarget reduction of suppressive cytokines and tumor-infiltrating T regulatory cells and MDSCs, increased CD8+ and CD4+ central memory T cells, and reduced frequency of MDSCs [31-34].”
Li, M.-X., Liu, X.-M., Zhang, X.-F., Zhang, J.-F., Wang, W.-L., Zhu, Y., Dong, J., Cheng, J.-W., Liu, Z.-W., Ma, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28536 · Cited by 459
Hong, X., Cui, B., Wang, M., Yang, Z., Wang, L., & Xu, Q. (2015) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.236.297 · Cited by 326
Cited by
Systemic immune-inflammation index for predicting prognosis of colorectal cancer
Chen, J.-H., Zhai, E.-T., Yuan, Y.-J., Wu, K.-M., Xu, J.-B., Peng, J.-J., Chen, C.-Q., He, Y.-L., & Cai, S.-R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i34.6261 · Cited by 723
Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis
Yang, R., Chang, Q., Meng, X., Gao, N., & Wang, W. (2018) · Journal of Cancer · doi:10.7150/jca.25691 · Cited by 441
Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer
Huang, H., Liu, Q., Zhu, L., Zhang, Y., Lu, X., Wu, Y., & Liu, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-39150-0 · Cited by 408
Fucà, G., Guarini, V., Antoniotti, C., Morano, F., Moretto, R., Corallo, S., Marmorino, F., Lonardi, S., Rimassa, L., Sartore-Bianchi, A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0894-7 · Cited by 398
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Metadata
- Authors
- Passardi, A., Scarpi, E., Cavanna, L., Dall’Agata, M., Tassinari, D., Leo, S., Bernardini, I., Gelsomino, F., Tamberi, S., Brandes, A. A., Tenti, E., Vespignani, R., Frassineti, G. L., Amadori, D., & De Giorgi, U.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-21
- Volume
- 7
- Issue
- 22
- Pages
- 33210-33219
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2340964024
- Cited by
- 156
- References
- 9
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. https://app.cochat.ai/papers/10.18632/oncotarget.8901
- The paper
- Passardi, A., Scarpi, E., Cavanna, L., Dall’Agata, M., Tassinari, D., Leo, S., Bernardini, I., Gelsomino, F., Tamberi, S., Brandes, A. A., Tenti, E., Vespignani, R., Frassineti, G. L., Amadori, D., & De Giorgi, U. (2016). Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.8901
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.